The FDA approved Varubi (rolapitant), from Tesaro Inc, to prevent delayed phase chemotherapy-induced nausea and vomiting (CINV). Varubi is approved...
Tesaro has submitted a New Drug Application (NDA) for an intravenous formulation of Varubi (rolapitant), for nausea, to the FDA....
OPKO Health, Inc. announces that its licensee, Tesaro Inc. received FDA approval for Varubi (rolapitant) i.v. in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting
OPKO Health, Inc. announces that its licensee, Tesaro Inc. received FDA approval for Varubi (rolapitant) i.v. in combination with other...
Tesaro reports anaphylaxis, anaphylactic shock and other hypersensitivity reactions with treatment by Varubi injectable emulsion.
Oral rolapitant (Varubi™; Varuby®), a long-acting neurokinin-1 (NK1) receptor antagonist (RA), is indicated in the USA and EU as part of an antiemetic regimen to prevent delayed chemotherapy-induced nausea and vomiting (CINV)...